JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2014
|
|
- Walter Wilson
- 5 years ago
- Views:
Transcription
1 JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled excellence in their search for ground breaking treatment options.
2 The office of research at Johns Hopkins Singapore (JHS) is fully integrated with the Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center (SKCCC) and is staffed by 5 investigators and 5 coordinators. The program continues to become more robust as additional studies are added annually. In 2014, the office of research coordinated and managed a total of 32 studies that fall into three (3) categories: Sixteen (16) new and existing studies opened for recruitment - Focus on treatments for the various types and stages of the following cancers: lung, breast, liver, gastric and follicular lymphoma. Eleven (11) studies closed for recruitment which included those studies that reached the targeted sample size. Five (5) studies have been submitted to the ethics committee and are pending approval. Please find the details of each study in the appendix. The research team has been very active recruiting patients for clinical trials and research studies. Sixteen (16) subjects were recruited for the triple negative breast cancer blood draw study and twenty-one (21) subjects undergoing therapeutic trials were treated in JHS outpatient clinics. There were a total of 230 outpatient encounters over the period for patients participating or enrolled in a JHS managed study. In one study (Diffused Large B-Cell Lymphoma) data for more than 100 patients was collected and is currently being analyzed. Additionally, a collaboration was initiated with Dr. Teh Bin Tean at Duke-NUS. The study includes analyzing transcriptome from tumor specimens of liver cancer patients. Three (3) JHS consultants had their research papers published in six (6) different academic journals: Jakob W. Buecheler, CB Howard, CJ de Bakker, S Goodall, ML Jones, T Win, Peng Tao, Tan CH, A Chopra, S M. Mahler, S Lim. Development of a protein nanoparticle platform for targeting EGFR expressing cancer cells. Journal of Chemical Technology and Biotechnology. 10 Sept Haaland B, Chopra A, Acharyya S, Fay AP, Lopes Gde L. Comparative effectiveness of approved first-line anti-angiogenic and molecularly targeted therapeutic agents in the treatment of good and intermediate risk metastatic clear cell renal cell carcinoma. BMC Cancer. 15 Aug
3 Gan YJ, Chopra A, Kanagalingam J. Subglottic Extramedullary Plasmacytoma With Light Chain Multiple Myeloma Masquerading as Adult-Onset Asthma. J Voice. 1 Feb Wei Hsu BY, Wang M, Zhang Y, Vijayaragavan V, Wong SY, Yuang-Chi Chang A, Bhakoo KK, Li X, Wang J. Silica F127 nanohybrid-encapsulated manganese oxide nanoparticles for optimized T1 magnetic resonance relaxivity. Nanoscale. 6(1): Chander S, Cooray P, McKendrick JJ, Wong SW, Ngan C, Michael M, Steel M, Ngan S. Achieving durable local control without surgery in unresectable, metastatic rectal cancer. ESTRO, Luen S, Wong SW, Mar V, Kelly JW, McLean C, McArthur GA, Haydon A. Primary tumour thickness is an important prognostic factor of survival in metastatic melanoma A retrospective audit of primary tumour characteristics. MOGA, The Office of Research had nearly one million ($1.0M) dollars under management during the period to finance research activities. These funds are primarily the result of pharmaceutical sponsorship as well as private industry. With the current open studies, soon to be activated studies, as well as potential studies on the horizon, the research team is looking forward to another busy and exciting year. Sincerely, Research Nurse Manager Xu Xiao Ying 2
4 APPENDIX Protocol Title Principle Investigator Indication Status During Research data base for women with triple negative breast cancer L. Bharwani Breast cancer 2. The study to compare the safety and efficacy of Lapatinib plus Transtuzumab plus an Aromatase Inhibitor (AI) versus transtuzumab plus an AI versus lapatinib plus an AI as first- or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive MBC who have received trastuzumab and endocrine therapies L. Bharwani Postmenopausal, HER2-positive metastatic breast cancer 3. A Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting 4. A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA- Associated Breast Cancer 5. NeoPHOEBE: Pi3k inhibition in Her2 Over Expressing Breast Cancer: A phase II, randomized, parallel cohort, two stage, double-blind, placebocontrolled study of neoadjuvant trastuzumab versus trastuzumab + BKM120 in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer" A Phase II, Non-comparative, label, Multicentre, International Study of MEDI4736, in Patients 6. with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum based Chemotherapy Regimen (ATLANTIC) L. Bharwani HER2-positive metastatic breast cancer failure 2 lines of treatments S. Yeap Advanced Unresectable BRCA-Associated Breast Cancer L. Bharwani Neo-adjuvant for HER2-positive A. Chopra failure 2 lines of treatment 7. A Prospective, randomized, multi-centre, open label, Phase III study of active specific immunotherapy with 1E10 MAb anti-idiotype vaccine plus Best Support treatment Vs Best Support treatment in patients with advanced. A. Chopra Maintenance Vaccine after 1 st treatment for 8. A Phase 2 -Label Rollover Study for subjects that have participated in an Astellas sponsored Linsitinib Trial A. Chopra Rollover for subject previously joined Linsitinib study 3
5 9. An open-label, non-randomized, multicenter phase 2 trial of AF802 given orally to patients who have ALK mutation and failed CRIZOTINIB treatment patients with ALK positive, failed Crizotinib 10. A Phase III, Randomised, Double-blind, Placebocontrolled, Multi-centre, International Study of MEDI4736 as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy (PACIFIC) A. Chopra Maintenance immunotherapy for patients after Cheomoradiation 11. A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS ) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis A. Chopra Immunotherapy for HCC patients failed treatments 12. A Multicenter, Randomized, -Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma A. Chopra 1st line treatment for HCC patients 13. Protocol XL : A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib A. Chopra Targeted therapy for HCC patients who failed Sorafenib 14. A Single-Arm, -Label Phase 2 Study of Nivolumab (BMS ) in Subjects with Relapsed or Refractory Follicular Lymphoma (FL) [CA ] 15. Immunohistochemical profiling of DLBCL in Asian patients and correlation with clinical outcomes. A. Chopra Relapsed or Refractory Follicular Lymphoma A. Chopra Data collection 16. A phase II (single center) study of neoadjuvant doxorubicin/cyclophosphamide followed by Eribulin chemotherapy (ACE) in operable HER2-negative breast cancer. 17. LUX Breast 1: An open label, randomised phase III trial of BIBW 2992 and vinorelbine versus trastuzumab and vinorelbine in patients with metastatic HER2-overexpressing breast cancer failing one prior trastuzumab treatment A. Chopra Neo-adjuvant for HER-2 negative L. Bharwani Metastatic HER2 overexpressing 18. Mutations of Epidermal Growth Factor Receptor in the blood of Patients with Advanced Non-Small Cell Lung Cancer Sample analysis 4
6 19. Randomized, Multicenter, Double-Blind, Phase 3 Trial Comparing the Efficacy of Ipilimumab in addidion to Paclitaxel and Carboplatin versus Placebo in addition to Paclitaxel and Carboplatin Alone in Subjects with Stage IV/Recurrent Non Small Cell Lung Cancer (). A. Chopra 20. An -label Randomized Phase III Trial of BMS versus Docetaxel in Previously Treated Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer () 21. LUX Lung 7: A randomised phase IIb trial of afatinib versus gefitinib as first line treatment of patients with EGFR mutation positive advanced adenocarcinoma of the lung. S. Yeap 22. A Randomized, -label, Multi-center, Phase 3 Study to Compare the Efficacy and Safety of Eribulin with Treatment of Physician s Choice in Subjects with Advanced Non-Small Cell Lung Cancer S. Yeap 23. LUX Lung 8: A randomised, Label Phase III Trial of Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung as Second Line Therapy Following First Line Platinum Based Chemotherapy Y.H. Chia 24. A Randomized, -label, Two-Arm Phase II Trial Comparing the Efficacy of Sequential Ipilimumab versus Best Supportive Care Following First-line Chemotherapy in Subjects with Unresectable Locally Advanced/Metastatic Gastric or Gastro-Esophageal Junction Cancer 25. A Pilot Study of Adjuvant Therapy of Gefitinib (Iressa ZD 1839) in patients with resectable HCC. 26. A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva ) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene 27. Integrated genome and transcriptome analysis of Human Liver S. Yeap Gastric HCC A. Chopra Liver tissue Sample analysis 28. A multicenter, randomized, double-blind Phase 3 study of Palbociclib (Oral CDK 4/6 inhibitor) plus letrozole versus placebo plus letrozole for the treatment of previously untreated east Asian postmenopausal women with ER (+), HER2 (-) advanced breast cancer [A ] Y.H. Chia Untreated east Asia postmenopausal women with ER (+), HER2 (-) 5
7 29. A Phase III, label, Randomised, Multi-centre, International Study of MEDI4736, given as monotherapy or in combination with Tremelimumab determined by PD-L1 expression versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC) A. Chopra failed 2 lines of treatment 30. A Randomized, Multicenter, Double-Blind, Multinational, Phase 3 Trial in Asia Comparing the Efficacy of Ipilimumab in addition to Paclitaxel and Carboplatin versus Placebo in addition to Paclitaxel and Carboplatin in Subjects with Stage IV/Recurrent Non Small Cell Lung Cancer () with Squamous Histology. Y.H. Chia Squamous 31. A Randomized, Double-Blind Phase 2 Study of JAK Inhibitor or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous, Non Small Cell Lung Cancer That Is Stage IIIB With Pleural/Pericardial Effusion, Stage IV, or Recurrent. Y.H. Chia Non-squamous 32. A Phase 2, Multicenter, International, Single Arm Study to Assess the Safety and Efficacy of Single Agent CC-486 (Oral Azacitidine) in Previously Treated Subjects With Locally Advanced or Metastatic Nasopharyngeal Carcinoma A. Chopra Nasopharyngeal Carcinoma 6
A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015
A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2015 15 years of excellence in patient care, research, and education The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled
More informationA JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2016
A JOHNS HOPKINS SINGAPORE ANNUAL RESEARCH REPORT 2016 The Promise of Medicine: The research team at Johns Hopkins Singapore provides unparalleled excellence in their search for ground breaking treatment
More informationOpen Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD
Open Clinical Trials: What s Out There Now Paula D. Ryan, MD, PhD Hanahan and Weinberg, 2000 Acquired Capabilities of Cancer Clinical Trials When should I consider a clinical trial? How do I find the right
More informationCLINICAL TRIALS ACC. Jul 2016
CLINICAL TRIALS ACC Jul 2016 Glioblastoma BRAIN A071102 A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
More information6/22/2017 TARGETING THE TARGETS IN 2017 TARGETING THE TARGETS IN 2017
TARGETING THE TARGETS IN 2017 Primary Care Focus Symposium July 1, 2017 Grace Wang MD I do not have any relevant financial relationships to disclose at this time TARGETING THE TARGETS IN 2017 What are
More informationStudies proceeding under pre HRA-Approval system (NHS Permission)
15/NW/0004 162679 Studies proceeding under pre HRA-roval system (NHS Permission) A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST- LINE METASTATIC COLORECTAL
More informationCommissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December
Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December 17 2010. 32/10 Imatinib for gastrointestinal stromal tumours (unresectable/metastatic) (update on
More informationJosé Baselga, MD, PhD
i n t e r v i e w José Baselga, MD, PhD Dr Baselga is Physician-in-Chief at Memorial Sloan-Kettering Cancer Center in New York, New York. Tracks 1-15 Track 1 Track 2 Track 3 Track 4 Track 5 Track 6 Track
More informationSUPPLEMENTARY INFORMATION
SUPPLEMENTARY NFORMATON n format provided by Melero et al. (AUGUST 2015) Supplementary nformation S3 Combinations including two or more immunotherapy agents based on PD-1/PD-L1 blockade. (Source: https://clinicaltrials.gov/
More informationOpen and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona
Open and Pending Trials Listing For Arizona Oncology Associates P.C. HOPE Division/ Tucson, Arizona Solid Tumor: USON 15180 / A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab
More informationManagement of advanced non small cell lung cancer
Management of advanced non small cell lung cancer Jean-Paul Sculier Intensive Care & Thoracic Oncology Institut Jules Bordet Université Libre de Bruxelles (ULB) www.pneumocancero.com Declaration No conflict
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Mars 2017 SEIN ADJUVANT OLYMPIA : A Phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant therapy in BRCA mutated
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: CP.PHAR.121 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Opdivo) Reference Number: CP.PHAR.121 Effective Date: 07.15 Last Review Date: 01.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationCENTER FOR CLINICAL TRIALS St. Luke s Medical Center. Ongoing Clinical Trials CANCER INSTITUTE (36)
CENTER FOR CLINICAL TRIALS St. Luke s Medical Center Ongoing Clinical Trials CANCER INSTITUTE (36) BLOOD TITLE : A Randomized, Two By Two Arm, Multicenter, Open-Label Phase III Study Of BMS-354825 Administered
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: November 30, 2018 Keytruda Description Keytruda
More informationMEDICAL PRIOR AUTHORIZATION
MEDICAL PRIOR AUTHORIZATION TAXOTERE (docetaxel) DOCEFREZ(docetaxel) docetaxel (generic) POLICY I. INDICATIONS The indications below including FDA-approved indications and compendial uses are considered
More informationPerformance in Initiating Clinical Research Q2 2016/17
Performance in Initiating Clinical Research Q2 2016/17 Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial Date of Receipt of Valid Research Application
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2017 SEIN NEO ADJUVANT Neo-RHEA : NEOadjuvant Biomarker ResearcH Study of Palbociclib in Estrogen Receptor Positive HER2 Negative Breast CAncer
More informationTitle Cancer Drug Phase Status
Clinical Trial Identifier Title Cancer Drug Phase Status NCT01164995 Study With Wee-1 Inhibitor MK-1775 and Carboplatin to Treat p53 Mutated Refractory and Resistant Ovarian Cancer Epithelial Ovarian Cancer
More informationThe Clinical Research E-News
Volume 4: ISSUE 6: August 28, 2012 The Clinical Research E-News Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Trials Opened at
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Herceptin) Reference Number: ERX.SPA.42 Effective Date: 07.01.16 Last Review Date: 05/17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the
More informationSCIENTIFIC PROGRAM. ASCO Direct 15CME HOURS. SCfHS ACCREDITED FOR. Current Update Sponsored by:
ASCO Direct Current Update 2017 24-25 November 2017 Crowne Plaza Hotel, Jeddah, KSA SCIENTIFIC PROGRAM Organized by: SCfHS ACCREDITED FOR 15CME HOURS Licensed by: Sponsored by: (+966) 11 462 2515 Ext.
More informationChemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer Chemotherapy With or Without Targeted Drugs* in Metastatic Breast Cancer * Substances without published evidence based on at
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationEuropean consortium study on the availability of anti-neoplastic medicines
European consortium study on the availability of anti-neoplastic medicines Nathan I Cherny Alexandru ENIU, MD, PhD Norman Levan Chair in Humanistic Chair, Emerging Countries Committee Medicine Department
More informationLondon Cancer New Drugs Group. February London Cancer New Drugs Group (LCNDG) Work Plan for the London Cancer Drugs Fund list.
February 2013 London Cancer New s Group (LCNDG) Work Plan for the London Cancer s Fund London Cancer s Fund List This Cancer s Fund (CDF) list of medicines and s is in two parts. 1. The standard list of
More informationBenefit Risk Analysis Of Decision-Making: Oncology
Benefit Risk Analysis Of Decision-Making: Oncology G.K. Raju, Ph.D. December 13 th 2016 Outline Background Approach Application to Oncology Non-Small Cell Lung Cancer Learnings & Ongoing Work Acknowledgements
More informationNCCN Guidelines for Central Nervous System Cancers V Follow-Up on 02/23/18
GLIO-3 and GLIO-4 Submission from Novocure Inc. (12/19/17 and 9/7/17) Please consider adding tumor treating fields in combination with temozolomide for the treatment of adult patients with newly diagnosed,
More informationOPEN TRIALS Accruals counted until 30-April Current Accrual
Disease group Breast OPEN TRIALS Trial Title Accrual Target IBCSG 48-14 POSITIVE IBCSG 50-14 OLYMPIA IBCSG 52-15 PALLAS SAKK 21/12 A study evaluating the pregnancy outcomes and safety of interrupting endocrine
More informationSummary of Research and Writing Activities in Oncology
Summary of Research and Writing Activities in Oncology Carole Alison Chrvala, PhD 919.545.2149 (Work) 919.951.5230 (Mobile) cchrvala@centurylink.net www.healthmattersmedwriting.com 1 Manuscripts, Posters,
More informationCorporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Juillet 2016 SEIN-NEO ADJUVANT LORELEI -GO28888-1319 BCG : A phase II randomized, double-blind, parallel cohort study of neoadjuvant letrozole + GDC-0032
More informationAll Studies by Indication
Therapeutic Area Protocol Number Drug/Device Phase Description Advanced malignancies 337 20101132 AMG 337 I " A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: May 14, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 6 Last Review Date: September 15, 2017 Keytruda Description Keytruda
More informationUniversity of Groningen. Health economics of targeted cancer therapies Mihajlovic, Jovan
University of Groningen Health economics of targeted therapies Mihajlovic, Jovan IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please
More informationEtudes cliniques Service d Oncologie - Radiothérapie
Etudes cliniques Service d Oncologie - Radiothérapie Décembre 2017 SEIN NEO ADJUVANT WO39392 (Impassion 031) : A phase III randomized study to investigate the efficacy and safety of Atezolizumab in combination
More informationNational Horizon Scanning Centre. Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer
Erlotinib (Tarceva) in combination with bevacizumab for advanced or metastatic non-small cell lung cancer This technology summary is based on information available at the time of research and a limited
More informationClinical Policy: Nivolumab (Opdivo) Reference Number: ERX.SPA.302 Effective Date:
Clinical Policy: (Opdivo) Reference Number: ERX.SPA.302 Effective Date: 03.01.19 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationPerformance in Initiating Clinical Research
Performance in Initiating Clinical Research January 2016 December 2016 NHS Permissions Site approval Research Ethics Committee Reference Number Integrated Research Application System Number Name of Trial
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationJohns Hopkins Clinical Update Webinar
Johns Hopkins Clinical Update Webinar Ben Ho Park, M.D., Ph.D. Department of Oncology Johns Hopkins University February 2015 This presentation is the intellectual property of the author/presenter. Contact
More informationDennis J Slamon, MD, PhD
I N T E R V I E W Dennis J Slamon, MD, PhD Dr Slamon is Professor of Medicine, Chief of the Division of Hematology/Oncology and Director of Clinical and Translational Research at UCLA s David Geffen School
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 7 Last Review Date: December 8, 2017 Keytruda Description Keytruda
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationThe Clinical Research E-News
The Clinical Research E-News Volume 6: ISSUE 5: June 12, 2014 Jefferson Kimmel Cancer Center Network: For urgent clinical trial questions or assistance please page: 877-656-9004 New Featured Trials Actively
More informationMultimedia Appendix 6 Educational Materials Table of Contents. Intervention Educational Materials Audio Script (version 1)
Multimedia Appendix 6 Educational Materials Table of Contents Intervention Educational Materials... 1 Audio Script (version 1)... 1 Text (version 1)... 5 Slides (version 1)... 17 Audio Script (version
More informationStrandAdvantage Tissue-Specific Cancer Genomic Tests. Empowering Crucial First-Line Therapy Decisions for Your Patient
StrandAdvantage Tissue-Specific Cancer Genomic Tests Empowering Crucial First-Line Therapy Decisions for Your Patient Harness the power of precision medicine with StrandAdvantage Precision medicine in
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 29 th Prioritization 4 th quarter 2016 General Information, efficacy and safety data Nicole Grössmann Sarah Wolf Claudia Wild Please note: Within
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationOncofocus. Patient Test Report
Oncofocus Patient Test Report Oncofocus Patient Test Report Oncologica UK Ltd, Suite 15-16, The Science Village, Chesterford Research Park, Cambridge, CB10 1XL www.oncologica.com - Tel: +44 (0)1223 785327
More informationA vision for HER2 future
School of Medical Oncology Department of Medical and Biological Sciences - University of Udine Department of Oncology - University Hospital of Udine A vision for HER2 future Current therapeutic algorithm
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationCyramza (ramucirumab)
Cyramza (ramucirumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 03/01/2017TBD03/01/2018 POLICY A. INDICATIONS The indications
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic Agents Original Policy Date: January 16, 2015 Subject: Opdivo Page:
More informationTechnology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer Technology appraisal guidance Published: 29 June 2011 nice.org.uk/guidance/ta227 NICE 2018. All rights reserved. Subject to
More informationErlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer
ERRATUM Erlotinib for the first-line treatment of EGFR-TK mutation positive non-small cell lung cancer This report was commissioned by the NIHR HTA Programme as project number 11/08 Completed 6 th January
More informationTrial Trial Name Opening of the first site. Enzalutamide in combination with metformin vs. enzalutamide in patients with CRPC
TRIALS TO BE ACTIVATED 2016/2017 Trial Trial Name Opening of the first site SAKK 41/13 SAKK 08/14 (IMPROVE) SAKK 16/14 SAKK 21/12 (Phase II part) GRAALL-2014 HD21 HOVON 103 SEL SAKK 30/10 IELSG-42 IELSG-43
More informationCorporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
More informationTargeted Cancer Therapies
Targeted Cancer Therapies Primary Care Training Programme 14 th February 2018 Sin Chong Lau Consultant in Medical Oncology Financial Disclosure Honoraria: Amgen, Pfizer, Roche, Sanofi, Servier Meetings:
More informationThe Clinical Research E-News
Volume 3: ISSUE 3: February 16, 2011 The Clinical Research E-News Now Open: RTOG 0631, Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis RTOG 1010, A Phase III Trial Evaluating
More informationKeytruda. Keytruda (pembrolizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.50 Subject: Keytruda Page: 1 of 9 Last Review Date: September 20, 2018 Keytruda Description Keytruda
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationKeytruda (pembrolizumab)
Keytruda (pembrolizumab) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 10/01/2015 Current Effective Date: 07/24/2017TBD03/01/2018 POLICY A. INDICATIONS The
More informationNational Horizon Scanning Centre. Sunitinib (Sutent) for advanced and/or metastatic breast cancer. December 2007
Sunitinib (Sutent) for advanced and/or metastatic breast cancer December 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationStudienverzeichnis Medizinische Onkologie
Studienverzeichnis Medizinische Onkologie Mammakarzinom, Gynäkologie 21/12 24/14 25/14 96/12 PALLAS I I Transdermal CR1447 (4-OH-testosterone) in endocrine responsive-her2 negative and triple negative-androgen
More informationMetastatic Breast Cancer What is new? Subtypes and variation?
Metastatic Breast Cancer What is new? Subtypes and variation? Anne Blaes, MD, MS University of Minnesota, Division of Hematology/Oncology Director, Adult Cancer Survivor Program Current estimates for metastatic
More informationIRB INDICATION Number ENROLLED
Revised 1/6/2011 OPEN TRIALS 2006-2011 INDICATION Number ENROLLED SPONSOR Title Provided Phase I AZA PH US 2007 PK 006 Celgene A Phase I, Open-Label, Multi-Center, Parallel Group Study to Assess the Pharmacokinetics
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Fall Conference Call 23 November 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including
More informationAppendix 2. Adjuvant Regimens. AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2
Appendix 2 Adjuvant Regimens AC doxorubin 60 mg/m 2 every 3 weeks x 4 cycles Cyclophosphamide 600 mg/m 2 CMF IV cyclophosphamide 600 mg/m 2 days 1 & 8 every 4 weeks methotrexate 40 mg/m 2 for 6 cycles
More informationAlimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage
Alimta (pemetrexed) Line(s) of Business: HMO; PPO; QUEST Integration Akamai Advantage Original Effective Date: 09/01/2007 Current Effective Date: TBD003/01/201703/01/2018 POLICY A. INDICATIONS The indications
More informationBREAST. Molecular Genetic Studies of Cancer Patients and Their Relatives GASTROINTESTINAL
BREAST HER2 Negative Metastatic or Locally Advanced Unresectable BRCA Associated Breast Cancer AbbVie M12-914 NCT02163694 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pembrolizumab (Keytruda) Reference Number: CP.PHAR.322 Effective Date: 07.01.18 Last Review Date: 11.17 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the
More informationCOME HOME Innovative Oncology Business Solutions, Inc.
Innovative Oncology Business Solutions, Inc. Breast Cancer Diagnostic/Therapeutic Pathway V11, April 2015 Required Structured Data Fields: ICD9 Code Stage Staging Components Performance Status Treatment
More informationALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
More informationMERCK ONCOLOGY OVERVIEW ASCO 2018 JUNE 4, 2018
MERCK ONCOLOGY OVERVIEW ASCO 218 JUNE 4, 218 Forward-Looking Statement of Merck & Co., Inc., Kenilworth, NJ, USA This presentation of Merck & Co., Inc., Kenilworth, N.J., USA (the company ) includes forward
More informationTargeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care
Targeted/Immunotherapy & Molecular Profiling State-of-the-art in Cancer Care Manmeet Ahluwalia, MD, FACP Miller Family Endowed Chair in Neuro-Oncology Director Brain Metastasis Research Program Cleveland
More informationMy name is Dr. David Ilson, Professor of Medicine at Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center in New York, New York.
Welcome to this CME/CE-certified activity entitled, Integrating the Latest Advances Into Clinical Experience: Data and Expert Insights From the 2016 Meeting on Gastrointestinal Cancers in San Francisco.
More informationCDK4 and CDK6 Inhibitor
CDK4 and CDK6 Inhibitor Abemaciclib, LY2835219 Derived from Shapiro GI. 1 Drug Discovery Platform: Cancer Cell Signaling JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus
More informationTraditional Approaches to Treating NSCLC, Part 2: Neoadjuvant Combined Modality, Locally Advanced, and Metastatic NSCLC
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationThoracic and head/neck oncology new developments
Thoracic and head/neck oncology new developments Goh Boon Cher Department of Hematology-Oncology National University Cancer Institute of Singapore Research Clinical Care Education Scope Lung cancer Screening
More informationTriple Negative Breast Cancer
GASCO 2016 San Antonio Breast Cancer Symposium Review Triple Negative Breast Cancer Amelia Zelnak, MD, MSc Atlanta Cancer Care Northside Hospital Cancer Institute Disclosures: consultant for Novartis,
More informationASCO 2014 Highlights*
ASCO 214 Highlights* Investor Meeting June 2, 214 *American Society of Clinical Oncology, May 3 June 3, 214 Forward-Looking Information During this meeting, we will make statements about the Company s
More informationNCCN Non Small Cell Lung Cancer V Meeting July 8, 2016
NSCL 3 Submission from Myriad requesting the following statement to be listed as an additional high risk factor in footnote p : For lung ADC, a highrisk 46 gene molecular prognostic score determined by
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Trastuzumab, as monotherapy and in combination with a taxane, for the treatment of metastatic breast cancer (to include
More informationManagement of Inflammatory Breast Cancer: Collaboration is the path forward
Management of Inflammatory Breast Cancer: Collaboration is the path forward Massimo Cristofanilli, M.D., F.A.C.P. Professor of Medicine Associate Director of Translational Research and Precision Medicine
More informationSTUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER
Contact: Anne Bancillon + 33 (0)6 70 93 75 28 STUDY FINDINGS PRESENTED ON TAXOTERE REGIMENS IN HEAD AND NECK, LUNG AND BREAST CANCER Key results of 42 nd annual meeting of the American Society of Clinical
More informationThe role of immune checkpoint inhibitors in non-small cell lung cancer
Review Article Page 1 of 9 The role of immune checkpoint inhibitors in non-small cell lung cancer Tiffany L. George 1, Erin M. Bertino 2 1 Divisions of Hematology and Medical Oncology, 2 Division of Medical
More informationDevelopment status of ONO-4538(nivolumab)1
Development status of ONO-4538(nivolumab)1 Development Code Target Disease JAPAN US/EU KOR/TAI ONO-4538 Melanoma(2 nd ~) Launched Launched (US) Filing (EU) Approved(KOR) Filing(TAI) ONO-4538 Melanoma(1
More informationWASHINGTON. Spokane Cheney. Olympia. Tri-Cities. Walla Walla. Portland North Central Oregon City OREGON. Mt. Vernon. Port Angeles
2 3 Mt. Vernon Port Angeles Bremerton Tacoma 5 5 Olympia Everett Edmonds Seattle 90 WASHINGTON 90 Spokane Cheney Pullman Longview 82 Tri-Cities Portland North Central Oregon City 5 84 OREGON Walla Walla
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationOpdivo. Opdivo (nivolumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.53 Subsection: Antineoplastic nts Original Policy Date: January 16, 2015 Subject: Opdivo Page: 1 of
More informationIt is a malignancy originating from breast tissue
59 Breast cancer 1 It is a malignancy originating from breast tissue including both early stages which are potentially curable, and metastatic breast cancer (MBC) which is usually incurable. Most breast
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More information